A COMPARISON OF THE EFFICACY OF STEROID PATCH CONTAINING BETAMETHASONE17 ,21DIPROPIONATE TO TOPICAL BETAMETHASONE17 ,21DIPROPIONATE TO TREAT IN CHRONIC HAND ECZEMA

Faculty of Medicine, Srinakharinwirot University0 sites56 target enrollmentApril 13, 2022

ConditionsMild to moderate chronic hand eczema Chronic hand eczema, Mild to moderate severity

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Mild to moderate chronic hand eczema
Sponsor: Faculty of Medicine, Srinakharinwirot University
Enrollment: 56
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The transdermal corticosteroid patch group demonstrated its safety and effectiveness, showing comparability to topical corticosteroids after 8 weeks of application. The patch's sustained-release features, when combined with once-daily application, have potential to enhance patient satisfaction and encourage better treatment adherence.

Registry

who.int

Start Date

April 13, 2022

End Date

July 24, 2022

Last Updated

last year

Study Type

Interventional

Sex

All

Investigators

Sponsor

Faculty of Medicine, Srinakharinwirot University

Eligibility Criteria

Inclusion Criteria

•1\. Female or male patients aged over 18 years old.
•2\. Patients who have been diagnosed as mild to moderate chronic hand
•eczema or have history of intermittent or persistent skin lesions such as eczematous or
•vesicles on both hands for more than 3 consecutive months or relapse more than twice
•a year with or without prior treatment.
•3\. Patients who have been assessed HECSI score as 0\-27 and defined as
•mild to moderate severity.
•4\. Patients who participate in the project voluntarily and sign the consent
•5\. Patients who are able to follow\-up examination in the 2nd, 4th, and 8th

Exclusion Criteria

•1\. Patients who have current or active bacterial, fungal, or viral infection of
•2\. Patients who allergic to component of ingredients in topical steroid
•ointment or patch using in this study as shown in Table 7 and 8\.
•3\. Female patients who are pregnant, lactating or planning to become
•pregnant during the study period.
•4\. Patients who have history of treatment with topical corticosteroids or
•topical calcineurin inhibitors within 2 weeks before and during this study.
•5\.Patients who have history of treatment with systemic corticosteroids,
•immunosuppressant such as cyclosporin, azathioprine, mycophenolate mofetil, and
•phototherapy within 4 weeks before and during this study